JP2008545793A5 - - Google Patents

Download PDF

Info

Publication number
JP2008545793A5
JP2008545793A5 JP2008515915A JP2008515915A JP2008545793A5 JP 2008545793 A5 JP2008545793 A5 JP 2008545793A5 JP 2008515915 A JP2008515915 A JP 2008515915A JP 2008515915 A JP2008515915 A JP 2008515915A JP 2008545793 A5 JP2008545793 A5 JP 2008545793A5
Authority
JP
Japan
Prior art keywords
group
hydrogen atom
aralkyl
alkyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008515915A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008545793A (ja
JP5461009B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/022268 external-priority patent/WO2006133353A2/en
Publication of JP2008545793A publication Critical patent/JP2008545793A/ja
Publication of JP2008545793A5 publication Critical patent/JP2008545793A5/ja
Application granted granted Critical
Publication of JP5461009B2 publication Critical patent/JP5461009B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2008515915A 2005-06-08 2006-06-08 非ペプチド及びペプチドbdnfニューロトロフィン類似体を用いた神経細胞生存促進法 Expired - Lifetime JP5461009B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68876705P 2005-06-08 2005-06-08
US60/688,767 2005-06-08
PCT/US2006/022268 WO2006133353A2 (en) 2005-06-08 2006-06-08 Methods of facilitating neural cell survival using non-peptide and peptide bdnf neurotrophin mimetics

Publications (3)

Publication Number Publication Date
JP2008545793A JP2008545793A (ja) 2008-12-18
JP2008545793A5 true JP2008545793A5 (enExample) 2009-07-30
JP5461009B2 JP5461009B2 (ja) 2014-04-02

Family

ID=37499118

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008515915A Expired - Lifetime JP5461009B2 (ja) 2005-06-08 2006-06-08 非ペプチド及びペプチドbdnfニューロトロフィン類似体を用いた神経細胞生存促進法

Country Status (5)

Country Link
US (2) US8686045B2 (enExample)
EP (3) EP2581440B1 (enExample)
JP (1) JP5461009B2 (enExample)
ES (1) ES2569881T3 (enExample)
WO (1) WO2006133353A2 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1606409T3 (pl) 2003-03-19 2011-02-28 Biogen Ma Inc Białko wiążące receptor Nogo
PT1776136E (pt) 2004-06-24 2012-12-05 Biogen Idec Inc Tratamento de estados que envolvem desmielinização
WO2006113097A2 (en) * 2005-04-15 2006-10-26 The University Of North Carolina At Chapel Hill Methods of facilitating cell survival using neurotrophin mimetics
US20110230479A1 (en) * 2005-04-15 2011-09-22 Longo Frank M Neurotrophin mimetics and uses thereof
EP2581440B1 (en) 2005-06-08 2016-03-16 The University of North Carolina At Chapel Hill Methods of facilitating neural cell survival using non-peptide and peptide BDNF neurotrophin mimetics
SI1904104T1 (sl) 2005-07-08 2013-12-31 Biogen Idec Ma Inc. Protitelesa SP35 in njihova uporaba
CA2672750A1 (en) * 2006-12-20 2008-07-03 Rinat Neuroscience Corporation Trkb agonists for treating autoimmune disorders
CA2701189C (en) * 2007-10-11 2017-05-16 Biogen Idec Ma Inc. Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell survival via administration of lingo-1 antagonists and trkb agonists
WO2009061500A1 (en) * 2007-11-08 2009-05-14 Biogen Idec Ma Inc. Use of lingo-4 antagonists in the treatment of conditions involving demyelination
WO2009086202A2 (en) * 2007-12-19 2009-07-09 Afraxis, Inc. Methods for treating neuropsychiatric conditions
US20100317715A1 (en) * 2007-12-21 2010-12-16 Vollrath Benedikt Methods for treating neuropsychiatric conditions
EP2315779A2 (en) 2008-07-09 2011-05-04 Biogen Idec MA Inc. Compositions comprising antibodies to lingo or fragments thereof
CA2762680C (en) 2009-05-21 2018-04-17 Chlorion Pharma, Inc. Methyl sulfanyl pyrmidmes useful as antiinflammatories, analgesics, and antiepileptics
KR101138048B1 (ko) 2009-11-06 2012-04-23 성균관대학교산학협력단 Bdnf의 발현을 증가시키는 신규 펩타이드 및 이를 포함하는 알츠하이머병 또는 파킨슨병의 예방 및 치료용 약학 조성물
WO2011060262A1 (en) 2009-11-12 2011-05-19 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
US10273219B2 (en) 2009-11-12 2019-04-30 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
WO2011070177A2 (en) 2009-12-11 2011-06-16 Baltic Technology Development, Ltd. Methods of facilitating neural cell survival using gdnf family ligand (gfl) mimetics or ret signaling pathway activators
US20120004310A1 (en) * 2010-05-28 2012-01-05 Longo Frank M Non-peptide bdnf neurotrophin mimetics
US9796780B2 (en) 2012-05-14 2017-10-24 Biogen Ma Inc. LINGO-2 antagonists for treatment of conditions involving motor neurons
JP6120311B2 (ja) * 2013-02-12 2017-04-26 学校法人銀杏学園 ポリフェノール化合物
US9828330B2 (en) 2013-03-15 2017-11-28 Pharmatrophix, Inc. Non-peptide BDNF neurotrophin mimetics
CA2901839A1 (en) * 2013-03-15 2014-09-18 Pharmatrophix, Inc. Non-peptide bdnf neurotrophin mimetics
AU2014250762A1 (en) 2013-04-12 2015-10-29 Achillion Pharmaceuticals, Inc. Highly active nucleoside derivative for the treatment of HCV
WO2016106050A1 (en) 2014-12-26 2016-06-30 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
WO2016112270A1 (en) 2015-01-08 2016-07-14 Biogen Ma Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders
EA201792261A1 (ru) * 2015-05-29 2018-04-30 Зе Боард Оф Трастис Оф Зе Лилэнд Стэнфорд Джуниор Юниверсити Нуклеозидные вещества для уменьшения вредной активности генов, содержащих удлиненные нуклеотидные повторы
WO2017019905A1 (en) 2015-07-28 2017-02-02 Otonomy, Inc. Treatment using truncated trk b and trk c antagonists
WO2017123826A1 (en) 2016-01-14 2017-07-20 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof
RU2020116571A (ru) 2017-12-07 2021-11-22 Эмори Юниверсити N4-гидроксицитидин и производные и связанные с этим противовирусные применения
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
BR112022024071A2 (pt) 2020-05-27 2022-12-20 Axial Therapeutics Inc Compostos moduladores de tlr2, composições farmacêuticas e usos dos mesmos
EP4074317A1 (en) 2021-04-14 2022-10-19 Bayer AG Phosphorus derivatives as novel sos1 inhibitors
SMT202500447T1 (it) 2021-11-02 2026-01-12 Flare Therapeutics Inc Agonisti inversi di pparg e loro usi
CN118401539A (zh) 2021-12-15 2024-07-26 兆维生物科技公司 官能化的n-乙酰半乳糖胺类似物
US12116382B2 (en) 2022-11-28 2024-10-15 Hongene Biotech Corporation Functionalized N-acetylgalactosamine analogs
CN116554123A (zh) * 2023-04-27 2023-08-08 山东大学 六种噻唑酰腙类化合物在抗肿瘤药物中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2109262A5 (enExample) 1970-10-08 1972-05-26 Inst Francais Du Petrole
US3953416A (en) * 1971-12-20 1976-04-27 Karl Folkers Synthetic decapeptide having the activity of the luteinizing hormone releasing hormone and method for manufacturing the same
JPS5025442B2 (enExample) * 1972-03-14 1975-08-23
DE2343037A1 (de) * 1973-08-25 1975-03-06 Hoechst Ag Arzneimittel mit antidepressiver wirkung
HU185535B (en) * 1982-05-25 1985-02-28 Mta Koezponti Hivatala Process for preparing new gonadoliberin derivatives
US5321029A (en) 1988-11-14 1994-06-14 Beecham-Wuelfing Gmbh & Co.K.G. Xanthines
GB9402331D0 (en) 1994-02-07 1994-03-30 Univ Mcgill Nerve growth factor structural analogs and their uses
AU4117396A (en) 1994-11-29 1996-06-19 Novartis Ag Morpholinoethylamide derivatives
US5958875A (en) 1996-03-29 1999-09-28 The Regents Of The University Of California Synthetic peptides derivatives with nerve growth factor-like neurotrophic activity
EP1008656A4 (en) * 1996-06-13 2000-09-20 Itoham Foods Inc METHOD FOR PRODUCING LH-RH DERIVATIVES
JP4676061B2 (ja) 1998-07-30 2011-04-27 アボット・ラボラトリーズ グルココルチコイド選択性薬剤
EP2112511B1 (en) 1999-03-17 2012-01-18 University Of North Carolina At Chapel Hill Method of screening candidate compounds for susceptibility to biliary excretion
US6583148B1 (en) 1999-04-08 2003-06-24 Krenitsky Pharmaceuticals, Inc. Neurotrophic substituted pyrimidines
WO2001052843A1 (en) 2000-01-18 2001-07-26 Mcgill University β-TURN PEPTIDOMIMETIC CYCLIC COMPOUNDS
AU2002228316A1 (en) 2001-01-29 2002-08-12 Insight Strategy And Marketing Ltd Carbazole derivatives and their uses as heparanase inhibitors
EP1553964A4 (en) 2002-09-25 2009-08-12 Georgia Tech Res Inst KETOAMID INHIBITORS IN CHRONIC NERVE DISEASES
WO2006113097A2 (en) 2005-04-15 2006-10-26 The University Of North Carolina At Chapel Hill Methods of facilitating cell survival using neurotrophin mimetics
EP2581440B1 (en) 2005-06-08 2016-03-16 The University of North Carolina At Chapel Hill Methods of facilitating neural cell survival using non-peptide and peptide BDNF neurotrophin mimetics

Similar Documents

Publication Publication Date Title
JP2009504748A5 (enExample)
TWI316942B (en) Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
JP5596680B2 (ja) 経口抗がん製剤
AU2004281959A1 (en) Novel dipeptidyl peptidase IV inhibitors used for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases
JP5461009B2 (ja) 非ペプチド及びペプチドbdnfニューロトロフィン類似体を用いた神経細胞生存促進法
JP2012530779A5 (enExample)
JP2019515908A5 (enExample)
KR20170086710A (ko) 피로의 치료 또는 예방 방법
JP2003509349A5 (enExample)
JP2007530577A5 (enExample)
JP2013513588A5 (enExample)
CN1071913A (zh) 反胺苯环醇n-氧化物及其对映异构件体和组合物,以及它们的应用
JP2017519775A5 (enExample)
JP2018138594A (ja) オナプリストン多形体及び使用方法
JP2007502832A5 (enExample)
JP2009541493A5 (enExample)
JP7830540B2 (ja) d-アンフェタミン化合物、組成物、ならびにそれを作製および使用するためのプロセス
EP1986647A2 (en) 4-acylaminopyridine derivative mediated neurogenesis
JP2008536844A5 (enExample)
ATE453617T1 (de) Substituierte n-arylbenzamide und verwandte verbindungen zur behandlung von amyloidkrankheiten und synukleinopathien
JP2025525588A (ja) カンナビノイドを含む連続的な送達システム及びその医薬的使用
CA2589744A1 (en) Pyrrolinidium derivatives as m3 muscarinic receptors
JP2006503095A5 (enExample)
KR20190087568A (ko) 카바메이트 화합물을 포함하는 비경구용 액상 제제
TWI285110B (en) Parkinson disease therapeutic agent